HOME >> MEDICINE >> NEWS
ESMO Scientific & Educational Conference (ESEC)

ESEC 2005 Highlights

  • The future in genomics and proteomics
  • Assessing risk in cancer patients
  • Avoiding side-effects of cancer therapy
  • Immunotherapies
  • Development of cancer-killing viruses
  • How communities can fight tobacco addiction
  • State-of-the-art oncology for various tumor types

Some other special features

  • New and updated ESMO Minimum Clinical Recommendations will present a global overview on current ESMO clinical guidelines used in everyday practice.
  • An ESMO Handbook on Oncological Emergencies (the first in a series) will launch and be distributed to all oncologists attending the conference.
  • A keynote lecture on the status of oncology in Central and Eastern European Countries will address differences in cancer epidemiology.
  • A fourth ESMO Patient Seminar on cancer in Eastern Europe will be organized for local patients to meet international oncologists, as well as share and discuss experiences on available cancer treatments.
  • The second Young Medical Oncologists Masterclass will provide young doctors with an expert insight and valuable suggestions on scientific publications and research.
  • Oncology Highlights of the most important advances in cancer treatment presented at other cancer conferences.

Scheduled Press Conference
Friday, 3 June 2005, 13:00-14:00
Topics to be confirmed.

Assisting you in Budapest
A Press Center will provide you with information, resources, and expert opinion. In addition to attending the Press Conference you will also have access to all the scientific sessions. (Please visit www.esmo.org/ESEC/Budapest2005/Program.htm for the ESEC preliminary program.)

Free Media Registration is granted to all bona fide media representatives.
The Media Registration Form can be requested to the ESMO Communication Dept. (

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
14-Mar-2005


Page: 1 2

Related medicine news :

1. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology
2. Scientific evidence for diets: dont believe everything you read
3. Original research presented at AAFP Annual Scientific Assembly
4. Scientific forum addresses menstrual cycle as vital sign
5. 23rd Annual Scientific Meeting of the American Pain Society to be held May 6-9 in Vancouver
6. UCLA professors James Heath, Gary Small named to Scientific Americans list of 50 visionaries
7. Scientific task force to examine usefulness of testosterone replacement therapy in older men
8. Scientific society recognizes womens contributions to the Manhattan Project
9. Scientific society offers development sessions for industrial members
10. Cedars-Sinai researchers to present findings at Amerian College of Cardiology Scientific Meeting
11. Scientific symposium focuses on nutritional beverages, August 26-28

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ESMO Scientific Educational Conference ESEC

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: